Lytix Biopharma AS (OSL:LYTIX)

Norway flag Norway · Delayed Price · Currency is NOK
7.20
+0.20 (2.86%)
Oct 3, 2025, 4:25 PM CET
2.86%
Market Cap477.83M
Revenue (ttm)608.00K
Net Income (ttm)-72.63M
Shares Out68.26M
EPS (ttm)-1.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,607
Average Volume21,191
Open7.00
Previous Close7.00
Day's Range6.98 - 7.20
52-Week Range4.55 - 10.00
Beta-0.43
RSI38.48
Earnings DateNov 13, 2025

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 7
Stock Exchange Oslo Børs
Ticker Symbol LYTIX
Full Company Profile

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.

Financial Statements

News

There is no news available yet.